Alumis has reached significant milestones recently, including the release of 52-week Phase II Open-Label Extension (OLE) data for ESK-001, an oral TYK2 inhibitor used in the treatment of psoriasis.

Alumis’s President and CEO, Martin Babler, has emphasized the potential benefits of the merger, including a stronger financial foundation and enhanced capabilities to advance treatments for ...

Alumis to Present at the Jefferies Global Healthcare Investor Conference. SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company ...

On Monday, Morgan Stanley resumed its coverage of Alumis Inc. (NASDAQ:ALMS) with an Overweight rating and a $23 price target after the company’s recent merger with Acelyrin and its Q1 2025 ...

Find the latest Option Chain Greeks data for Alumis Inc. Common Stock (ALMS) at Nasdaq.com.

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme, aimed to assess the safety and efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor, ESK-001, for treating adults with ...

Alumis Inc (Symbol: ALMS) saw options trading volume of 4,858 contracts, representing approximately 485,800 underlying shares or approximately 43% of ALMS's average daily trading volume over the ...

Find the latest Alumis Inc. (ALMS) stock quote, history, news and other vital information to help you with your stock trading and investing.